Colin J. Sutherland

Dr Colin Sutherland, BSc PhD MPH Professor of Parasitology Co-Director: LSHTM Malaria Centre (2018- ) Deputy Director (Science): PHE Malaria Reference Laboratory (2018- ) Dr Sutherland joined the London School of Hygiene & Tropical Medicine in 1998 as a Research Fellow to work with Prof Geoffrey Targett on the adhesion of Plasmodium falciparum gametocytes to host endothelium. Colin then coordinated a series of Wellcome Trust-funded clinical trials which measured the effect of antimalarial combination therapy on transmission of P. falciparum in Farafenni, The Gambia from 2000 to 2002. This led further to work focussed on parasite drug resistance in several African countries within the Gates Malaria Partnership from 2000 - 2008, the FP7-funded MALACTRES consortium from 2008-2013, and the EDCTP-funded WANECAM consortium from 2012 to present. Since 2004 Colin has also contributed to the work of the Public Health England Malaria Reference Laboratory in LSHTM, and as an honorary Clinical Scientist in the Department of Clinical Parasitology, Hospital for Tropical Disease, London, where he has contributed to the development of new molecular diagnostics for malaria and in studies of the genetics/genomics of all Plasmodium species that infect humans. The Sutherland research group in the Department of Immunology & Infection at LSHTM has successfully produced 15 PhD graduates to date, and currently comprises 2 PhD students, 2 Post-docs and 1 Technician, and has current research projects on: 1) the genetics, genomics & epidemiology of ovale malaria 2) potential of gametocyte stages of P. falciparum as targets of chemotherapy and vaccine-elicited immunity 3) genetic polymorphisms in P. falciparum associated with resistance to ACT drugs in vivo and in vitro 4) in vitro drug susceptibility of P. falciparum and P. knowlesi 5) molecular genetics of drug resistance in P. falciparum in North Sumatera, Indonesia 6) molecular genetics, genomics and epidemiology of Plasmodium knowlesi among human hosts in Indonesia 7) Genome-editing approaches to understand K13-independent mechanisms of reduced artemisinin susceptibility in P. falciparum